State of Alaska Department of Revenue Has $513,000 Stock Position in Heska Co. (NASDAQ:HSKA)

State of Alaska Department of Revenue reduced its stake in Heska Co. (NASDAQ:HSKA – Get Rating) by 13.6% during the third quarter, Holdings Channel.com reports. The fund owned 7,044 shares of the medical research company’s stock after selling 1,110 shares during the period. State of Alaska Department of Revenue’s holdings in Heska were worth $513,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lazard Asset Management LLC acquired a new position in shares of Heska in the second quarter worth approximately $39,000. Point72 Hong Kong Ltd acquired a new position in shares of Heska in the first quarter worth approximately $57,000. Mutual of America Capital Management LLC lifted its stake in shares of Heska by 17.4% in the second quarter. Mutual of America Capital Management LLC now owns 1,812 shares of the medical research company’s stock worth $171,000 after acquiring an additional 269 shares during the period. Federated Hermes Inc. acquired a new position in shares of Heska in the second quarter worth approximately $185,000. Finally, Inspire Investing LLC lifted its stake in shares of Heska by 33.0% in the second quarter. Inspire Investing LLC now owns 2,256 shares of the medical research company’s stock worth $213,000 after acquiring an additional 560 shares during the period. 99.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Kevin S. Wilson purchased 11,018 shares of the firm’s stock in a transaction that occurred on Friday, January 6th. The stock was acquired at an average price of $58.62 per share, for a total transaction of $645,875.16. Following the completion of the acquisition, the chief executive officer now owns 167,072 shares of the company’s stock, valued at approximately $9,793,760.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Kevin S. Wilson purchased 3,440 shares of the firm’s stock in a transaction that occurred on Thursday, December 22nd. The stock was acquired at an average price of $59.64 per share, for a total transaction of $205,161.60. Following the completion of the acquisition, the chief executive officer now owns 156,054 shares of the company’s stock, valued at approximately $9,307,060.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin S. Wilson purchased 11,018 shares of the firm’s stock in a transaction that occurred on Friday, January 6th. The shares were bought at an average price of $58.62 per share, with a total value of $645,875.16. Following the acquisition, the chief executive officer now directly owns 167,072 shares of the company’s stock, valued at approximately $9,793,760.64. The disclosure for this purchase can be found here. 11.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

HSKA has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their price target on Heska from $175.00 to $150.00 and set an “overweight” rating on the stock in a research note on Monday, October 17th. StockNews.com initiated coverage on Heska in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Morgan Stanley lowered Heska from an “equal weight” rating to an “underweight” rating and set a $58.00 price target on the stock. in a research note on Friday, January 6th. Alliance Global Partners dropped their price target on Heska from $155.00 to $119.00 and set a “buy” rating on the stock in a research note on Wednesday, November 9th. Finally, Piper Sandler dropped their price target on Heska from $170.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Heska presently has a consensus rating of “Hold” and an average price target of $123.00.

Heska Trading Up 2.2 %

NASDAQ HSKA opened at $73.47 on Friday. The company has a market cap of $795.39 million, a price-to-earnings ratio of -46.80 and a beta of 1.40. Heska Co. has a 52 week low of $57.83 and a 52 week high of $158.27. The business has a 50 day moving average price of $65.15 and a 200-day moving average price of $77.70. The company has a quick ratio of 5.61, a current ratio of 7.18 and a debt-to-equity ratio of 0.24.

Heska (NASDAQ:HSKA – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The medical research company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.09 by $0.15. The firm had revenue of $61.49 million during the quarter, compared to the consensus estimate of $69.72 million. Heska had a positive return on equity of 0.09% and a negative net margin of 6.26%. As a group, equities analysts expect that Heska Co. will post 0.27 earnings per share for the current fiscal year.

About Heska

(Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.